GlassScriptPhysician profile
Melissa Barham Jackson
NPI 1578049276
$3,958.65
in general payments reported to CMS, 2019-2025
37 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,678 · 2022: $1,438 · 2023: $457 · 2024: $161 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $570.37 | 2021-2024 | |
| Ucb, INC. | $461.62 | 2021-2023 | Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $433.57 | 2022 | |
| Abbvie INC. | $389.97 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $311.16 | 2021 | |
| Sk Life Science, INC. | $297.45 | 2021-2023 | |
| Pfizer INC. | $163.14 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $151.43 | 2021-2025 | Ajovy, Austedo Xr |
| Neurocrine Biosciences, INC. | $138.60 | 2021-2023 | Ongentys, Ingrezza |
| Medtronic, INC. | $110.66 | 2021-2022 | |
| Acorda Therapeutics, INC | $102.57 | 2021-2023 | Inbrija |
| Genzyme Corporation | $92.12 | 2021 | |
| Acadia Pharmaceuticals INC | $69.98 | 2021 | |
| Jazz Pharmaceuticals INC. | $59.09 | 2021-2024 | |
| Lundbeck LLC | $58.56 | 2022-2023 | Vyepti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $51.16 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $48.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $43.04 | 2021 | |
| Merz Pharmaceuticals, LLC | $41.09 | 2022 | |
| Horizon Therapeutics Plc | $38.94 | 2021 | |
| Biogen, INC. | $32.93 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.42 | 2022-2023 | Onpattro |
| Alexion Pharmaceuticals, INC. | $26.95 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.64 | 2021 | |
| Ani Pharmaceuticals, INC. | $22.61 | 2023 | Purified Cortrophin Gel |
| Grifols USA, LLC | $21.62 | 2021 | |
| Axsome Therapeutics, INC. | $21.16 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $18.55 | 2021 | |
| Eisai INC. | $15.34 | 2021 | |
| Allergan, INC. | $13.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.12 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.07 | 2021 | |
| Ns Pharma, INC. | $12.79 | 2022 | |
| Tanabe Pharma America, INC. | $12.00 | 2021 | |
| Amgen INC. | $11.77 | 2021 | |
| Upsher-Smith Laboratories LLC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.